Menu Search
Equities

Aequus Pharmaceuticals Inc

AEQ:DEU

Aequus Pharmaceuticals Inc

Actions
  • Price (EUR)0.016
  • Today's Change0.001 / 6.67%
  • Shares traded0.00
  • 1 Year change+100.00%
  • Beta--
Data delayed at least 15 minutes, as of May 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company focused on developing, advancing, and promoting differentiated products. The Company is engaged in the sale and marketing of several commercial products in ophthalmology and transplant. Its pipeline products include Evolve Intensive Gel, Evolve Daily Intensive, SCOPE Portfolio, Zimed PF and REV-0100 / ReVision. Evolve Intensive Gel and Evolve Daily Intensive contains lubricating eye drops intended for use in the relief of discomfort that arises from dry eye sensations, including dryness, soreness, feelings of grit, and irritation. Zimed PF is a preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. It plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license.

  • Revenue in CAD (TTM)215.21k
  • Net income in CAD-2.88m
  • Incorporated2013
  • Employees12.00
  • Location
    Aequus Pharmaceuticals Inc595 Burrard Street, Suite 2600VANCOUVER V7X 1L3CanadaCAN
  • Phone+1 (604) 336-7906
  • Fax+1 (604) 336-7906
  • Websitehttps://www.aequuspharma.ca/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.